Chung Shan Medical University is a medical university located in South District, Taichung, Taiwan. Chung Shan Medical University Hospital is affiliated with the university.

During the past decade, Chung Shan Medical University conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 17 clinical trials were completed, i.e. on average, 37.8% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 16 clinical trials were completed. i.e. 72.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chung Shan Medical University" #1 sponsor was "Chung Shan Medical University" with 24 trials, followed by "Eli Lilly and Company" with 13 trials sponsored, "Pfizer" with 4 trials sponsored, "Arcus Biosciences, Inc." with 2 trials sponsored and "AVEO Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chung Shan Medical University" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Changhua Christian Hospital" with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "TCI Co., Ltd." with 2 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Chung Shan Medical University" are "Atopic Dermatitis" (4 trials), "Healthy" (3 trials), "Hypertension" (3 trials), "Lung Cancer" (3 trials) and "Obesity" (3 trials). Many other conditions were trialed in "Chung Shan Medical University" in a lesser frequency.

Most popular intervention types in "Chung Shan Medical University" are "Drug" (21 trials), "Dietary Supplement" (17 trials), "Other" (7 trials), "Biological" (4 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Baricitinib" (5 trials), "placebo" (4 trials), "Tirzepatide" (3 trials) and "Domvanalimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Chung Shan Medical University" are 47 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Chung Shan Medical University". undefined are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 31 completed trials in Chung Shan Medical University, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Chung Shan Medical University, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 25 trials that are defined as “Not Applicable".